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At the end of 2009, 5.25 million persons
were receiving antiretroviral therapy
(ART) worldwide, representing an 10-
fold increase over a period of 5 years [1].
The global scale-up of ART has led to an
inevitable increase in HIV drug re-
sistance (HIVDR) and a pool of resistant
virus available to establish new in-
fections. The report by Sungkanuparph
et al in this issue highlights the need for
strengthened national, regional, and
global surveillance of HIVDR for the
purpose of informing public health
policy [2]. Because .739,000 persons
are receiving ART in East, South, and
Southeast Asia [3], the paucity of data
on emergence of HIVDR in populations
taking ART in this region is striking.
Broadly, there are 3 categories of
HIVDR. Acquired HIVDR occurs when
resistance mutations are selected for by
drug selective pressure in individuals re-
ceiving ART. In individuals receiving
ART, acquired HIVDR may emerge
because of suboptimal adherence, treat-
ment interruptions, inadequate plasma
drug concentrations, or the use of sub-
optimal drug or drug combinations.
Transmitted HIVDR occurs when pre-
viously uninfected individuals are in-
fected with drug-resistant virus. The term
‘‘transmitted HIVDR’’ is appropriately
applied only to HIVDR detected in re-
cently infected individuals. The third
category is HIVDR detected in in-
dividuals with chronic infection in which
drug resistance can be either transmitted
or acquired. This last category is impor-
tant because it is the focus of the analysis
presented by Sungkanuparph et al.
Transmitted HIVDR may persist for
many months or years in the absence of
drug selective pressure (ie, in individuals
naive to ART), although duration varies
by mutation. For example, the reverse
transcriptase (RT) mutation M184V,
which confers resistance to the nucleo-
side reverse-transcriptase inhibitors
(NRTI) lamivudine and emtricitabine,
reduces viral fitness, whereas the K103N
and Y181C mutations that cause re-
sistance to the nonnucleoside reverse
transcriptase inhibitors (NNRTIs) ne-
virapine (NVP) and efavirenz (EFV)
have little impact on viral fitness [4]. In
an individual infected with a virus with
drug resistance mutations that only
modestly reduce fitness, most but not all
mutant species are likely to persist over
long periods. Specifically, M41L, T69N,
K103N, and some T215 variants show
little tendency to revert to wild-type over
time. However, it is theoretically possi-
ble that some transmitted drug-resistant
HIV strains may have reverted to wild-
type before genotypic assessment [5–7]
or have decreased to levels below the
threshold of detection by population-
based sequencing, persisting as minority
variants or archived resistance in pro-
viral DNA [8]. Sungkanuparph et al
rightly indicate that this may result in an
underestimation of transmitted re-
sistance in chronically infected patients.
However, some HIVDR detected in
chronically infected patients may be ac-
quired because of previous ART expo-
sure not elicited at the time of testing
because of social desirability bias, desire
of individuals to participate in a partic-
ular study, or interviewer bias. None-
theless, there is value in surveying
HIVDR in populations starting ART in
settings where transmitted drug re-
sistance is known to occur at high levels,
and results provide data about the likely
efficacy of currently available regimens
in patients starting ART.
An important consideration in de-
termining the prevalence of HIVDR is
the method used to classify mutations.
When assessing transmitted HIVDR, the
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World Health Organization recom-
mends use of the World Health Orga-
nization surveillance drug resistance
mutations list [9]. Mutations included
on this list are recognized as (1) causing
or contributing to HIVDR, (2) non-
polymorphic, (3) subtype independent,
and (4) emerging under drug selective
pressure. Surveys of transmitted re-
sistance using this list may be compared
over time and between regions. When
assessing acquired HIVDR or HIVDR in
chronically infected patients, clinical-
based algorithms, such as the Stanford
HIV Drug Resistance database [10, 11],
which considers the contribution of
polymorphisms and mutation combi-
nation to overall drug susceptibility, or
the International AIDS Society (IAS)–
USA HIV mutations list, are used [12].
Sungkanuparph et al assessed HIVDR
in 682 patients with chronic HIV in-
fection (median CD4 cell count, 100
cells/mm3) who started ART at 8 sites in
Hong Kong, Malaysia, and Thailand and
reported a 13.8% prevalence among
patients of >1 HIVDR mutation. The
report is a baseline analysis of a study
designed to assess individual patient and
ART clinical factors associated with viral
suppression 12 and 24 months after
initiation of ART. In this analysis, the
authors used the IAS-USA 2008 muta-
tions list [12] and reported no associa-
tion between HIVDR and patient age,
sex, location, ethnicity, risk exposure,
HIV-1 subtype, hepatitis B or C co-
infection, and HIV load. Of interest, the
median CD4 cell count was observed to
be lower in patients with HIVDR than in
patients without it (66 cells/mm3vs 108;
P 5 .009). The authors are correct to
assert that patients may have been in-
fected with a drug-resistant strain during
an earlier era when mono- or dual
therapy was being used in Asia. How-
ever, because the population studied had
advanced disease, it raises the possibility
of previous undisclosed exposures to
ART, including prevention of mother to
child transmission, resulting in acquired
HIVDR, which makes interpretation and
development of subsequent public
health recommendations challenging.
A total of 8.4% of patients were re-
ported to have NRTI resistance. The
most frequently observed mutation,
K70R (7.6%), confers resistance to zi-
dovudine and potential low-level re-
sistance to stavudine. T69S, present in
.7% of specimens, is selected by NRTIs,
but its effect on NRTI susceptibility is
unknown. Although the overall reported
prevalence of NNRTI resistance was
6.5%, it is reassuring that only 4 patients
(0.6%) had HIVDR to EFV and NVP,
because they are the NNRTIs used in the
region’s first-line regimens. V108I, as-
sociated with low-level resistance to all
NNRTIs except etravirine (ETR), was
observed in only 0.1% and A98G, asso-
ciated with NVP and delavirdine re-
sistance in only .1%. The surprisingly
high prevalence of reported NNRTI re-
sistance was driven by the inclusion of
the naturally occurring polymorphism
conferring potential low level resistance
to all NNRTIs (V179D; 3.2%) and by the
inclusion of the polymorphic V90I
(0.7%), A98G (0.1%), and V106I
(1.9%), which were associated with ETR
response in the DUET studies designed
to evaluate ETV efficacy [13] but have
little effect on ETR susceptibility. Be-
cause ETR is not widely used in the re-
gion, it is unlikely that these mutations
had been selected for therapy. Further-
more, because the population is sus-
ceptible to EFV, NVP, and protease
inhibitors, potential low-level ETR re-
sistance is unlikely to be of significant
public health importance. Nevertheless,
documentation of polymorphisms asso-
ciated with decreased response to ETV
before the start of ART is important in
light of recent studies demonstrating
association between HIV-1 CR01_AE,
the predominant HIV-1 subtype re-
ported in this cohort, and ETV cross-
resistance in patients experiencing NVP
and EFV treatment failure [14]. As
expected, protease inhibitor resistance
was low, detected in only .1% of pa-
tients.
On the basis of previous reports clas-
sifying transmitted drug-resistant HIV at
,5% in Vietnam and Thailand, the au-
thors concluded that HIVDR is in-
creasing in the region. However, it is
important to clarify that the surveys re-
ferred to by Sungkanuparph et al that
were performed in Hanoi, Vietnam, and
Bangkok, Thailand, classified transmitted
resistance in very specific populations of
recently infected individuals in a defined
geographical region with use of the
World Health Organization surveillance
drug resistance mutations list, which ex-
cludes naturally occurring poly-
morphisms [9, 11, 15, 16]. These surveys
use very different methods, and therefore
their use as a baseline comparator of
HIVDR may be misleading. Although it
may be difficult to infer an increase of
HIVDR in the region based on their
findings, the findings by Sungkanuparph
et al are important and highlight the need
for continued vigilance and routine sur-
veillance of HIVDR at the population
level in the region.
Sungkanuparph et al suggest the need
for individual HIVDR testing before
initiation of ART in the region. How-
ever, this study with patients drawn
from 8 sites in 3 countries documents
low levels of HIVDR to the major
components of first-line ART regimens;
thus, the results do not support a rec-
ommendation for individual patient
drug resistance testing. The article by
Sungkanuparph et al suggests that the
currently available standard first-line
regimens used in the region are likely to
be effective and durable at the pop-
ulation level. Of importance, in most if
not all resource-limited settings, HIVDR
testing is neither routinely available nor
recommended for individual patient
management. Genotyping is expensive
and complex; moreover, the limited
availability of alternate regimens permits
little change based on genotyping results.
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Although, in the future, HIVDR testing
may become more accessible as tech-
nology gaps are reduced and lower cost
tests and point-of-care assays, new
specimen technologies, and point mu-
tation assays become available, we have
a collective responsibility to use available
resources wisely to maximize treatment
optimization and minimize HIVDR.
The lack of accessible individual
HIVDR testing need never limit opti-
mization of patient care and global ef-
forts to minimize HIVDR. Care may be
optimized and HIVDR minimized
through the strengthening of health care
systems informed by robust pro-
grammatic evaluation of factors known
to be associated with the emergence of
HIVDR and by routine, standardized,
population-based surveillance of trans-
mitted and acquired HIVDR. Focusing
available resources on optimizing re-
tention of patients in care (both those
receiving ART and pre-ART), support-
ing adherence to therapy, minimizing
toxicities by improved pharmacovigi-
lance, and ensuring a continuous supply
of quality assured drugs are critical to
the success of global ART scale-up.
Failure to proactively identify and ad-
dress programmatic challenges associ-
ated with HIVDR is likely to lead to
inadequate response of available first-
and second-line regimens. As ART con-
tinues to be scaled-up rapidly, it is
a global imperative that programmatic
assessment informed by routine surveil-
lance of transmitted and acquired
HIVDR be performed to best inform
national, regional, and global ART
policy. Greater funding and infrastruc-
ture are urgently needed to support
ongoing routine surveillance of HIVDR
and increased efforts in supporting na-
tional and regional ART programs in
optimizing care and treatment of HIV
infected patients, which has the added
value of minimizing HIVDR.
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